ccnl1 Antibody

What is the biological function of Cyclin L1 (CCNL1) and why is it relevant for research?

Cyclin L1 (CCNL1) is a member of the cyclin family implicated in RNA processing and splicing mechanisms. Unlike cyclins primarily involved in cell cycle regulation, CCNL1 contains an RS domain (Ser-Arg rich proteins) that confers splicing activity. CCNL1 functions as an immediate early gene induced by several growth factors and may regulate G0-G1 cell-cycle progression. Research has demonstrated its localization to nuclear speckles in tumor cells, consistent with its putative role in RNA splicing . The protein is predominantly expressed in the nuclei of epithelial cells, with some cells showing discrete additional cytoplasmic staining. Recent studies have also implicated CCNL1 in viral pathogenesis, particularly in Hepatitis B virus (HBV) infection, where it regulates HBV RNA transcription and replication by modulating RNA Polymerase II phosphorylation and activity . These diverse functions make CCNL1 a significant target for research across multiple fields including cancer biology and virology.

How do I select the appropriate CCNL1 antibody for my specific research application?

Selecting the appropriate CCNL1 antibody requires careful consideration of several factors based on your experimental design:

• Target epitope: Determine which region of CCNL1 you need to detect. Different antibodies target varying regions such as N-terminal (AA 1-172), C-terminal, or specific internal domains (AA 314-369, AA 32-81, etc.) . The epitope selection is critical if you're studying specific isoforms or if post-translational modifications might mask certain regions.

• Host species and clonality: Available options include mouse monoclonal and rabbit polyclonal antibodies. Monoclonal antibodies offer higher specificity but recognize single epitopes, while polyclonal antibodies provide stronger signals by binding multiple epitopes but may have higher cross-reactivity .

• Application compatibility: Verify the antibody's validated applications (WB, IHC, IF, ELISA, IP) align with your experimental needs. Some antibodies perform better in certain applications than others .

• Species reactivity: Confirm the antibody recognizes CCNL1 in your experimental model organism. Available antibodies show reactivity against human, mouse, rat, and sometimes additional species like cow, pig, and xenopus .

• Validation data: Request validation data demonstrating the antibody's performance in applications similar to your planned experiments.

What are the standard methodologies for detecting CCNL1 expression in tissue samples?

The detection of CCNL1 expression in tissue samples commonly employs these methodological approaches:

Immunohistochemistry (IHC): This technique allows visualization of CCNL1 protein within the tissue architecture. Standard protocols involve:

• Tissue fixation and embedding, typically in formalin and paraffin

• Sectioning at 3-5 μm thickness

• Antigen retrieval (pressure-cooking for 3 min in 0.1 M citrate buffer pH 6.0 has been validated)

• Overnight incubation at 4°C with appropriate CCNL1 antibody dilution (e.g., 1/1000)

• Signal development using avidin-biotin peroxidase complex method

• Include negative controls lacking primary antibody

Immunofluorescence (IF): Provides higher resolution subcellular localization information. CCNL1 typically shows nuclear speckle patterns consistent with its role in RNA processing .

RNA expression analysis: Quantitative PCR remains the gold standard for measuring CCNL1 gene expression:

• Total RNA isolation followed by cDNA preparation

• qPCR using LightCycler or similar systems with SYBR green detection

• Use of appropriate reference genes (e.g., RPLP0) for normalization

• Relative CCNL1 gene expression calculated by normalization to internal controls and then to normal tissue samples

In research settings, a value ≥1.7-fold higher expression compared to normal tissue is typically considered overexpression for CCNL1 .

How can I distinguish between different CCNL1 isoforms using antibody-based approaches?

Distinguishing between CCNL1 isoforms requires strategic antibody selection and experimental design:

Isoform-specific antibody selection: The α isoform of CCNL1 contains a unique C-terminal sequence with an RS domain. Select antibodies specifically targeting this region, such as those raised against the peptide SKHHGGRSGHCRHRR, which binds exclusively to the C-terminal of the α isoform . Alternative isoforms lacking this domain require antibodies targeting distinct regions.

Western blot analysis with size discrimination: CCNL1 isoforms differ in molecular weight due to alternative splicing. Design your Western blot to effectively resolve these differences:

• Use lower percentage (8-10%) polyacrylamide gels for better separation of high molecular weight proteins

• Include longer run times and appropriate molecular weight markers

• Employ gradient gels (4-15%) to maximize resolution across the relevant molecular weight range

• Compare band patterns with recombinant standards of known isoforms

Immunoprecipitation followed by mass spectrometry: This advanced approach can definitively identify specific isoforms:

• Immunoprecipitate CCNL1 using a pan-CCNL1 antibody

• Separate proteins by SDS-PAGE

• Extract bands at expected molecular weights

• Perform tryptic digestion

• Analyze by liquid chromatography-tandem mass spectrometry (LC-MS/MS)

• Identify isoform-specific peptide signatures

Immunohistochemistry with phosphorylation-specific antibodies: Since CCNL1 function involves phosphorylation of RNA Polymerase II, using antibodies that detect specifically phosphorylated CCNL1 can help differentiate functionally distinct populations .

What are the challenges in quantifying CCNL1 gene amplification and protein overexpression correlation in tumor samples?

Researchers face several methodological challenges when correlating CCNL1 gene amplification with protein overexpression:

Discordance between amplification and expression: Studies have reported that while CCNL1 overexpression occurs in approximately 57% of head and neck squamous cell carcinomas (HNSCCs), gene amplification is detected in only 26% of cases . This discrepancy suggests that mechanisms beyond gene dosage regulate CCNL1 expression, similar to observations with other oncogenes like cyclin D1.

Technical variability in amplification detection:

• Varied sensitivity between methods (FISH vs. quantitative PCR)

• Inconsistent thresholds for defining amplification (≥1.5-fold is commonly used)

• Heterogeneity within tumor samples requiring microdissection

• Need for appropriate reference genes (CAPN3 and HBB have been validated as internal controls)

Standardization of overexpression criteria:

• Lack of consensus on expression cutoffs (≥1.7-fold is commonly used)

• Reference tissue variability (matched normal vs. tissue panels)

• Requirement for appropriate normalization genes that remain stable across tumor samples

Correlation analysis challenges:

Research has shown that while amplification correlates with overexpression (p=0.049), CCNL1 overexpression was detected in 34% of tumors without gene amplification, indicating that comprehensive assessment requires both DNA and RNA/protein analysis .

How can CCNL1 antibodies be utilized to investigate its role in RNA Polymerase II phosphorylation and viral replication?

CCNL1's newly discovered role in viral replication, particularly for HBV, can be investigated using antibody-based techniques through these approaches:

Chromatin Immunoprecipitation (ChIP) assays:

• Cross-link protein-DNA complexes in infected cells

• Immunoprecipitate with CCNL1 antibodies

• Analyze precipitation of viral DNA (such as HBV cccDNA)

• Perform parallel ChIP with antibodies against RNA Polymerase II (both total and phosphorylated forms)

• Quantify enrichment using qPCR with viral genome-specific primers

This technique has revealed that CCNL1 knockdown inhibits the binding of phospho-(Ser2-Ser5) RNAPII and total RNAPII to HBV cccDNA, along with reduced binding of pan-acetylated H3ac and H3K27ac marks .

Co-immunoprecipitation (Co-IP) for protein-protein interactions:

• Prepare nuclear extracts from infected and control cells

• Immunoprecipitate with CCNL1 antibody

• Probe Western blots for RNA Polymerase II and its phosphorylated forms

• Perform reciprocal Co-IP with RNAPII antibodies

• Include RNase treatment controls to distinguish RNA-dependent interactions

In vitro kinase assays:

• Immunopurify CCNL1 from cells using specific antibodies

• Incubate with recombinant C-terminal domain (CTD) of RNAPII

• Measure phosphorylation using phospho-specific antibodies

• Compare kinase activity with and without viral infection

Immunofluorescence co-localization studies:

• Perform dual staining with CCNL1 antibody and viral markers

• Include phospho-RNAPII (Ser2) antibodies to assess co-localization with transcription sites

• Analyze nuclear speckle patterns in relation to viral replication centers

• Quantify co-localization using appropriate statistical measures

Research applying these techniques has demonstrated that CCNL1 can phosphorylate the C-terminal domain of RNA Polymerase II at serine 2 (S2), likely regulating HBV transcription and establishing CCNL1 as a potential host susceptibility factor for HBV infection .

What are the optimal protocols for detecting CCNL1 using Western blotting?

Western blotting for CCNL1 requires careful optimization to achieve specific detection. The following protocol incorporates technical considerations specific to CCNL1:

Sample preparation:

• Extract proteins using RIPA buffer supplemented with phosphatase inhibitors (critical as CCNL1 is involved in phosphorylation events)

• Include protease inhibitor cocktail to prevent degradation

• Sonicate briefly to shear DNA and reduce sample viscosity

• Determine protein concentration using Bradford or BCA assay

• Prepare samples with 4X Laemmli buffer containing DTT or β-mercaptoethanol

Gel electrophoresis considerations:

• Use 10% SDS-PAGE gels for optimal resolution of CCNL1 (molecular weight range)

• Load 20-50 μg of total protein per well

• Include positive control (recombinant CCNL1) and molecular weight markers

Transfer and detection:

• Transfer to PVDF membrane at 100V for 1 hour or 30V overnight at 4°C

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary CCNL1 antibody (1:1000 dilution) overnight at 4°C

• Wash 3× with TBST, 10 minutes each

• Incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

• Wash 3× with TBST, 10 minutes each

• Develop using enhanced chemiluminescence (ECL) substrate

• Image using digital imaging system

Troubleshooting common issues:

For CCNL1 specifically, note that the GST-tagged recombinant protein will appear at approximately 26 kDa higher molecular weight than the native protein due to the GST tag .

How should researchers interpret and validate CCNL1 immunohistochemistry staining patterns in different tissue contexts?

Interpreting CCNL1 immunohistochemistry (IHC) requires understanding its typical localization patterns and implementing appropriate validation strategies:

Expected staining patterns:

• Normal tissues: Weak nuclear staining primarily in parabasal cells of epithelium

• Tumor tissues: Predominantly nuclear localization with discrete additional cytoplasmic staining in some cells

• Subcellular pattern: Nuclear speckles compatible with CCNL1's role in RNA splicing

Validation approaches:

• Positive and negative controls:

  • Include known positive tissue (HNSCC with confirmed CCNL1 overexpression)

  • Include negative controls omitting primary antibody

  • Use siRNA-treated cell blocks (with confirmed CCNL1 knockdown) as biological negative controls

  • Compare with fluorescent-tagged CCNL1 expression patterns in transfected cells

• Orthogonal validation:

  • Correlate IHC findings with RNA expression levels from the same tissues

  • Confirm nuclear localization using subcellular fractionation followed by Western blotting

  • Verify specificity using multiple antibodies targeting different CCNL1 epitopes

• Quantification methods:

  • Establish a scoring system based on staining intensity (0-3+)

  • Assess percentage of positive cells (0-100%)

  • Calculate H-score (intensity × percentage) for semi-quantitative comparison

  • Consider digital image analysis for objective quantification

• Interpreting heterogeneity:

  • Document intratumoral heterogeneity patterns, which are common for CCNL1

  • Correlate with histological features (differentiation, invasion front)

  • Consider multiple tissue blocks per case for comprehensive assessment

Clinical-pathological correlation considerations:

• Studies have shown that CCNL1 expression levels in tumors are not significantly associated with clinico-pathological features such as tumor site, size, differentiation, or lymph node involvement

• The absence of prognostic significance (survival or relapse) suggests CCNL1 may be involved in tumor initiation rather than progression

• Consider tissue-specific expression patterns when interpreting results across different cancer types

What strategies can researchers employ to investigate CCNL1's role in RNA splicing using antibody-based approaches?

Investigating CCNL1's role in RNA splicing requires specialized antibody-based methodologies:

RNA Immunoprecipitation (RIP):

• Cross-link RNA-protein complexes in living cells

• Lyse cells and immunoprecipitate with CCNL1 antibody

• Extract co-precipitated RNA

• Perform RT-PCR or RNA-seq to identify bound transcripts

• Compare with input RNA and IgG control immunoprecipitation

• Focus analysis on pre-mRNAs known to undergo alternative splicing

Chromatin Immunoprecipitation and RNA Sequencing (ChIP-seq):

• Perform ChIP with CCNL1 antibody

• Sequence precipitated DNA to identify genomic binding sites

• Analyze for enrichment near alternatively spliced exons

• Correlate binding patterns with splicing outcomes from parallel RNA-seq data

Immunofluorescence co-localization with splicing factors:

• Co-stain cells with CCNL1 antibody and antibodies against known splicing factors (e.g., SC35, U2AF65, hnRNPs)

• Visualize using confocal microscopy

• Quantify co-localization using Pearson's correlation coefficient

• Compare localization patterns before and after transcriptional inhibition

Proximity Ligation Assay (PLA):

• Use primary antibodies against CCNL1 and splicing factors

• Apply species-specific PLA probes

• Only when proteins are in close proximity (<40 nm) will a fluorescent signal be generated

• Quantify interaction signals per nucleus

Functional splicing assays with CCNL1 manipulation:

• Design minigene splicing reporters containing alternatively spliced exons

• Transfect cells with reporters alongside CCNL1 overexpression vectors or siRNA

• Extract RNA and analyze splicing patterns by RT-PCR

• Compare effects on exons with and without RS domain binding motifs

This comprehensive approach can help elucidate whether CCNL1's role in RNA processing affects specific transcripts or represents a global effect on splicing machinery, potentially explaining its involvement in both cancer progression and viral replication.

How do CCNL1 expression patterns differ between cancer types and what antibody-based methods best capture these differences?

CCNL1 expression shows distinctive patterns across cancer types, requiring tailored antibody-based approaches:

Cancer-specific expression patterns:

• Head and neck squamous cell carcinoma (HNSCC): Overexpression in 57% of cases, with amplification in 26%

• Hepatocellular carcinoma: Enhanced expression in chronic hepatitis B patients compared to those with resolved infection, suggesting a link to viral persistence

• Other epithelial tumors: Variable expression requiring comparative analysis

Optimal antibody-based detection methods:

• Tissue microarray (TMA) immunohistochemistry:

  • Enables high-throughput comparison across multiple tumor types

  • Standardizes staining conditions for direct comparison

  • Can be coupled with digital image analysis for quantitative assessment

  • Allows correlation with clinical outcomes in large cohorts

• Multiplex immunofluorescence:

  • Permits simultaneous detection of CCNL1 with lineage markers and other cyclins

  • Enables single-cell analysis of expression heterogeneity

  • Can identify rare subpopulations with distinct expression patterns

  • Particularly valuable for examining tumor microenvironment interactions

• Reverse phase protein array (RPPA):

  • Allows quantitative analysis of CCNL1 protein levels across large sample sets

  • Requires highly specific antibodies validated for this platform

  • Enables correlation with other signaling pathway components

  • Supports comprehensive proteomic profiling complementary to genomic data

Comparative analysis considerations:

Researchers should consider that heterogeneous staining is observed throughout tumor sections and between different tumors , necessitating robust sampling strategies and quantification methods.

What methodologies can researchers use to investigate the functional relationship between CCNL1 and viral infections?

Recent discoveries linking CCNL1 to HBV infection regulation require specialized methodological approaches:

RNA interference-based functional studies:

• Design siRNA targeting CCNL1 with appropriate controls

• Transfect cells susceptible to viral infection

• Confirm knockdown efficiency by Western blot and qRT-PCR

• Assess viral replication through multiple parameters:

  • Viral antigen production (e.g., HBsAg by ELISA)

  • Viral RNA levels by qRT-PCR

  • Viral DNA replication by Southern blot or qPCR

  • Viral protein expression by Western blot

This approach has demonstrated that RNAi-mediated knockdown of CCNL1 results in approximately 40% reduction in HBsAg levels .

Gain-of-function studies:

• Generate expression vectors for wild-type CCNL1

• Create functionally relevant mutants (e.g., kinase-dead variants)

• Transfect into cells along with viral molecular clones or infectious virus

• Measure effects on viral replication parameters

Mechanistic investigation using chromatin immunoprecipitation (ChIP):

• Perform ChIP with antibodies against:

  • CCNL1

  • Total RNA Polymerase II

  • Phospho-(Ser2-Ser5) RNA Polymerase II

  • Histone marks (H3ac, H3K27ac)

• Quantify enrichment on viral DNA (e.g., HBV cccDNA)

• Compare results with and without CCNL1 knockdown

Studies have shown that CCNL1 knockdown inhibits the binding of both total and phospho-RNAPII to HBV cccDNA, as well as key histone marks, suggesting its role in regulating cccDNA-dependent viral transcription .

Clinical correlation studies:

• Collect liver biopsy specimens from:

  • Chronic hepatitis B patients

  • Patients with resolved HBV infection

  • Healthy controls

• Assess CCNL1 expression by immunohistochemistry and qRT-PCR

• Correlate with viral markers and disease parameters

• Perform multivariate analysis to identify independent associations

Evidence suggests enhanced CCNL1 expression in chronic hepatitis B patients compared to those with resolved infection, supporting a functional link between this host factor and chronic HBV infection .

How can researchers validate the specificity of their CCNL1 antibody across different experimental platforms?

Comprehensive validation of CCNL1 antibodies across platforms is essential for reliable research outcomes:

Western blot validation:

• Test with positive controls (cells with confirmed CCNL1 expression)

• Include negative controls:

  • CCNL1 knockdown by siRNA

  • CCNL1 knockout cell lines (if available)

  • Non-expressing tissues/cell lines

• Confirm expected molecular weight (accounting for isoforms and post-translational modifications)

• Verify single bands or explainable multiple bands

• Pre-absorb antibody with immunizing peptide to confirm specificity

Immunoprecipitation validation:

• Perform IP followed by Western blot with the same or different CCNL1 antibody

• Confirm enrichment compared to input

• Verify absence of signal in IgG control IP

• Validate by mass spectrometry identification of immunoprecipitated proteins

Immunohistochemistry/Immunofluorescence validation:

• Compare staining pattern with published CCNL1 localization (nuclear speckles)

• Verify concordance with Western blot results in the same samples

• Confirm specificity through:

  • Peptide competition assays

  • Comparison with CCNL1-GFP transfected cells

  • Parallel staining with multiple antibodies against different CCNL1 epitopes

• Include proper controls:

  • Omission of primary antibody

  • Isotype control antibody

  • CCNL1 knockdown tissues/cells

Cross-platform validation matrix:

Additional considerations:

• Validate in multiple cell types to account for context-dependent epitope accessibility

• Test fixation sensitivity for IHC/IF applications

• Verify cross-reactivity with orthologous proteins from relevant model organisms

• Document lot-to-lot variation through standardized validation procedures

Thorough validation across platforms ensures reliable interpretation of CCNL1-related findings and facilitates comparison across studies.

What are the emerging research areas involving CCNL1 antibodies that researchers should be aware of?

CCNL1 research is evolving rapidly, with several emerging areas where antibody-based approaches will be crucial:

CCNL1 in viral host-pathogen interactions: Beyond the established role in HBV replication, researchers should explore CCNL1's potential involvement in other viral infections. The discovery that CCNL1 can serve as a host susceptibility factor for HBV suggests it may play similar roles in other viruses that rely on host transcriptional machinery . Antibody-based screening methods could help identify viral-specific interactions.

Post-translational modifications of CCNL1: The functional regulation of CCNL1 likely involves phosphorylation and other modifications. Developing and utilizing modification-specific antibodies (phospho-CCNL1, acetyl-CCNL1, etc.) would enhance our understanding of how CCNL1 activity is regulated in different cellular contexts and disease states.

CCNL1 in cancer immunotherapy strategies: As CCNL1 is overexpressed in certain cancers , exploring its potential as an immunotherapy target through antibody-drug conjugates or CAR-T approaches represents an intriguing research direction. This would require developing highly specific antibodies suitable for therapeutic applications.

Single-cell analysis of CCNL1 expression: Given the heterogeneous expression observed in tumors , single-cell approaches using CCNL1 antibodies could reveal distinct cell populations and their functional significance. This could help explain why CCNL1 overexpression doesn't consistently correlate with clinical outcomes despite its frequent amplification.

CCNL1 in alternative splicing regulation: The RS domain suggests involvement in splicing regulation, but the specific transcripts affected remain largely unknown. RIP-seq approaches using CCNL1 antibodies could identify the RNA repertoire directly bound by CCNL1, potentially revealing disease-relevant splicing targets.

These emerging areas highlight the continuing importance of developing and validating specific CCNL1 antibodies for advancing our understanding of this multifunctional protein.

How might researchers integrate antibody-based CCNL1 detection with other omics approaches for comprehensive analysis?

Multi-omics integration with CCNL1 antibody-based detection can provide unprecedented insights:

Integration with genomics:

• Combine CCNL1 ChIP-seq with whole genome sequencing to correlate binding sites with genetic variants

• Integrate copy number variation data with CCNL1 protein expression to refine understanding of gene-protein relationships

• Correlate CCNL1 amplification status with protein localization and phosphorylation state

Integration with transcriptomics:

• Pair CCNL1 RIP-seq with RNA-seq after CCNL1 manipulation to identify direct and indirect effects on the transcriptome

• Correlate alternative splicing events (detected by RNA-seq) with CCNL1 protein levels and localization

• Integrate nascent RNA sequencing with CCNL1 ChIP-seq to determine immediate transcriptional impacts

Integration with proteomics:

• Combine CCNL1 immunoprecipitation with mass spectrometry to identify interaction partners

• Correlate CCNL1 expression (by IHC) with proteome-wide changes (by mass spectrometry)

• Use proximity labeling approaches (BioID, APEX) with CCNL1 antibody validation to map the CCNL1 interactome

Integration with epigenomics:

• Correlate CCNL1 ChIP-seq with histone modification maps to understand chromatin context preferences

• Integrate CCNL1 binding data with DNA methylation profiles to identify epigenetic regulatory mechanisms

• Combine CCNL1 localization data with chromatin accessibility maps (ATAC-seq) to assess relationship to open chromatin

Data integration workflow:

• Multi-level data collection:

  • CCNL1 protein: IHC, IF, Western blot, IP-MS

  • Genomic status: WGS, targeted sequencing of 3q25-28

  • Transcriptome: RNA-seq with splice junction analysis

  • Epigenome: ChIP-seq for histones and transcription factors

• Computational integration:

  • Apply machine learning approaches to identify patterns across data types

  • Construct protein-centric networks integrating multiple data types

  • Develop predictive models of CCNL1 function based on multi-omic signatures

• Functional validation:

  • Test predicted interactions or functions using targeted antibody-based assays

  • Validate computational findings with orthogonal experimental approaches

This integrative approach can reveal context-specific functions of CCNL1 and potentially identify novel therapeutic targets in pathways regulated by this multifunctional protein.